Avapro provides no benefit for heart-failure patients in study
Avapro was no better than placebo in lowering deaths or hospitalizations because of cardiovascular events in people with a hard-to-treat type of heart failure, according to a study that monitored 4,128 patients for more than four years on average. Bristol-Myers Squibb and Sanofi-Aventis funded the clinical trial of their product, which belongs to a class of blood-pressure treatments called angiotensin-receptor blockers. The results are similar to previous findings on a different ARB and another hypertension drug known as an ACE-inhibitor.
Wall Street Journal, The | 11/11
This story published in AHIP Solutions SmartBrief on 11/12/2008
Higher ARB doses mean better outcomes for heart failure
Wednesday, November 18, 2009
Home care is good option for elderly heart failure patients
Tuesday, September 29, 2009
Many heart failure patients make quick return to hospital
Wednesday, November 11, 2009
|
AHIP Solutions SmartBrief
Designed specifically for health care executives like you, AHIP Solutions SmartBrief is a FREE daily e-mail newsletter. It provides the latest need-to-know news and industry information that maximizes your time, giving you an edge over your competition. Learn more |
|